Press

MindBio Therapeutics Corp. Announces Major Genetic Discovery in Microdosing Research

Sep 5 • 3 min read

MindBio Therapeutics Corp. reported it has made a major discovery from genetic testing clinical trial participants in the largest LSD-Microdosing randomized double blind and placebo-controlled trial ever completed. The data analysis comes as the Company begins two Phase 2 clinical trials using its proprietary form of LSD for Microdosing MB22001. These trials are a world…

California Psychedelic Decriminalisation Bill Clears Appropriations Committee with Amendments

Sep 1 • 4 min read

California’s psychedelic decriminalisation bill, SB-58, was passed with amendments by the Assembly Appropriations Committee. Its amended version will now head to the assembly floor for a final vote before going to the Governor’s desk. The bill was passed as part of the California Assembly Appropriations Committee’s ‘suspense day’, whereby bills placed on the suspense file…

Lophos Announces Listing on the Canadian Securities Exchange

Aug 31 • 2 min read

Lophos Holdings Inc. (“Lophos“, or the “Company“) is pleased to announce that its common shares have been approved for listing on the Canadian Securities Exchange (the “CSE“) and the Company expects to commence trading on the CSE on or around September 06, 2023, under the ticker symbol “MESC“. The CUSIP/ISIN numbers for the common shares…

PSYC Acquires Stock Day Media to Help Bolster Revenue Production Capacity

Aug 31 • 6 min read

PSYC Corporation (OTC Pink Market: PSYC) (“PSYC”, “PSYC Corp” or the “Company”), parent company to Spotlight Media Corporation (“SMC” or the “wholly owned subsidiary”), an evolving multimedia holding company and leading media authority for emerging industries such as medicinal psychedelics, is pleased to announce the Company, through its wholly-owned subsidiary, Spotlight Media Corporation, has completed…

Filament Health Enters Licensing Agreement With Reset Pharma

Aug 31 • 3 min read

Reset Pharma has licensed Filament’s botanical psilocybin drug candidate for a phase 2 clinical trial studying demoralization syndrome Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or “Filament Health”), a clinical-stage natural psychedelic drug development company, today announced that it has entered into a licensing agreement with Reset Pharmaceuticals Inc. (“Reset Pharma”), a privately…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436